FDA approves first two interchangeable biosimilars to Regeneron's blockbuster Eylea
Eylea will eventually have competition in the US, as the FDA approved two interchangeable biosimilars.
Monday’s approvals for Biocon Biologics’ Yesafili and Samsung Bioepis and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.